Andreas Schreiner, Novartis - Qepler Summits And Conferences

Andreas Schreiner

Director of Validation, Manufacturing Science and Technology
Novartis
Basel, Switzerland
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Andreas Schreiner graduated from the University Erlangen, Germany in 1996 in Chemical Engineering. After a Ph.D. and a scholarship at the University College London he joint Roche Vitamins as Head of Solids Processing; since 2006 Andreas Schreiner worked for Novartis in various departments with increasing responsibilities from project leader to global technology platform leader; currently he is heading the validation activities for pharmaceutical production of solid dosage forms.Since 2013 he works for the Manufacturing Science & Technology Department as Validation Head for Solid Dosage Forms.

Andreas Schreiner is appointed board member at various scientific organisations (Executive Board of European Federation of Chemical Engineers (EFCE), Swiss Society for Process Engineers (SGVC), Industrial Society for Pharmaceutical Engineering (ISPE), Swiss Laboratory of Material Science and Technology (EMPA)).

Since 2013 he works for the Manufacturing Science & Technology Department as Validation Head for Solid Dosage Forms.

Related Sessions:

Highly Potent APIs
Summit 2019

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 20 Feb 2019
  • Berlin, DE
  • Pharma
Day 1: Wednesday, 20 February 2019
BLOCK: CLEANING VALIDATION.
CASE STUDY: Cleaning Validation as one driver to prevent cross-contamination.
  • Introduction to health based exposure limits
  • Regulatory requirements and audit experience
  • Case study
View Details

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 2: Thursday, 20 February 2020
CASE STUDY: Production of Highly Active Substances in Shared Facilities - A Risk for Patients?
  • Potential cross contamination of highly potent drug products and mitigations
  • Health based exposure limits
  • Case studies for oral and inhalable dosage forms
View Details

3rd Annual Highly Potent
APIs Summit 2023

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 22 Feb 2023
  • Virtual,
  • Pharma
Day 2: Thursday, 23 February 2023
CASE STUDY: Cleaning validation – Enhanced approach required for Highly Potent APIs?
  • Health Authority Requirements
  • Case Studies
  • Cleaning Process Design Phase
View Details